AstraZeneca pays a bumper bonus and bolsters its board March 20, 2014 ASTRAZENECA boss Pascal Soriot was awarded a bumper bonus for 2013, equivalent to 94 per cent of the maximum the pharmaceuticals giant could have paid its CEO. The company’s annual report, published yesterday, cited several acquisitions that have bolstered its pipeline. Despite declining sales and profits, Soriot received a £1.87m bonus for 2013, taking his [...]
AstraZeneca’s shares slide due to lost patents February 6, 2014 ASTRAZENECA’S share price dropped almost two per cent yesterday, after the pharmaceuticals giant warned of a decline in revenues this year. The FTSE 100-quoted firm said that 2013’s six per cent fall in revenue to $25.7bn (£15.8bn) was in line with expectations, reflecting the continuing impact of loss of exclusivity on several brands. New heart [...]
AstraZeneca’s shares lifted by pipeline hopes January 14, 2014 ASTRAZENECA expects new drugs and a recent diabetes deal to offset a wave of patent expiries and return it to growth faster than analysts predict, with 2017 revenue likely to be broadly in line with the 2013 level. The company’s forecast implies a potential $3bn upgrade to the consensus estimate from analysts and marks an [...]
AstraZeneca in biotech deal to boost pipeline January 8, 2014 ASTRAZENECA has signed a deal with private British biotech company Immunocore to boost its experimental cancer drug pipeline as it seeks to find new medicines to replace those going off patent. Immunocore is developing drugs known as ImmTACs that exploit the power of the body’s own immune system to find and kill diseased cells. AstraZeneca [...]
AstraZeneca victorious in patent battle July 3, 2008 Shares in AstraZeneca, the drugs giant, jumped nearly 5 per cent yesterday after it won a key patent battle in America over Seroquel, its anti-psychotic drug and second-best seller. The decision by a US court to award a summary judgment in AstraZeneca’s favour avoids the need for a full trial and means that generic copies [...]
Killing the cure October 28, 2005 Some say British drugs companies should be able to profit in order to reinvest in newer drugs for the greater good. Some say their profits come on the back of scientific fraud. It is perhaps one of the great puzzles of British business. As a nation we spend less on medicines than our European neighbours, [...]